Ben Zhang

Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial

Yunpeng Yang, Song Qu, Jingao Li et al. · The Lancet Oncology · 2021 · 429 citations

Medicine, Clinical Trials, Immune Checkpoint Inhibitor +8

Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Jie Wang, Caicun Zhou, Wenxiu Yao et al. · The Lancet Oncology · 2022 · 361 citations

Oncology, Pharmacology, Bronchial Neoplasm +5

Novel Common Genetic Susceptibility Loci for Colorectal Cancer

Stephanie L. Schmit, Christopher K. Edlund, Fredrick R. Schumacher et al. · JNCI Journal of the National Cancer Institute · 2018 · 187 citations · Full text

Genome-wide association analysis in East Asians identifies breast cancer susceptibility loci at 1q32.1, 5q14.3 and 15q26.1

Qiuyin Cai, Ben Zhang, Hyuna Sung et al. · Nature Genetics · 2014 · 159 citations · Full text

Cancer Susceptibility, Genome-wide Association Study, Medicine +10

Genome-Wide Association Study in East Asians Identifies Novel Susceptibility Loci for Breast Cancer

Jirong Long, Qiuyin Cai, Hyuna Sung et al. · PLoS Genetics · 2012 · 155 citations · Full text